<DOC>
	<DOCNO>NCT02077114</DOCNO>
	<brief_summary>The purpose study ass whether vaccine contain small fragment protein IDO , may present cancer cell cell immune system , safe use combination either Ipilimumab Vemurafenib treatment malignant melanoma metastasize .</brief_summary>
	<brief_title>Vaccination With Peptides Combination With Either Ipilimumab Vemurafenib Treatment Unresectable Stage III IV Malignant Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criterion patient 1 . Age ≥ 18 2 . Measurable disease accord RECIST 1.1 3 . ECOG performance status ≤ 2 4 . Patients asymptomatic brain metastasis allow ( treatment systemic glucocorticoid compatible participation ) 5 . Women childbearing potential must negative shCG prior initiation treatment , use effective contraception treatment 26 week last treatment . Safe contraception include : Birth control pill , intrauterine device , depot injection progesterone , subdermal implantation ( eg Implanon ) , hormonal vaginal ring transdermal patch . All patient must meet inclusion criterion treatment group belong . Inclusion criterion Vemurafenib peptide vaccine 1 . Histologic confirm stage III ( nonoperable ) stage IV melanoma BRAF V600 document mutation 2 . Patients fully recover previous systemic topical treatment metastatic malignant melanoma 3 . Adequate haematological , renal hepatic function : Neutrophils ≥ 1.5 x 10^9 / l Platelet count ≥ 100 x 10^9 / l Hemoglobin ≥ 5.6 mmol / l Serum creatinine ≤ 1.5 time upper normal limit AST ALT ≤ 2.5 time upper normal limit ( ≤ 5 time upper normal limit consider increase due liver metastasis ) Serum bilirubin ≤ 1.5 time upper normal limit Alkaline phosphatase ≤ 2.5 time upper normal limit ( ≤ 5 time upper normal limit consider increase due liver metastasis ) Inclusion criterion Ipilimumab peptide vaccine 1 . Histologic verify stage III ( nonoperable ) stage IV malignant melanoma 2 . Patients previously treat antiCTLA4 therapy include , unless treatment stop due lack efficacy side effect 3 . There must least 21 day since last systemic treatment malignant melanoma patient must free side effect treatment . After palliative radiotherapy elsewhere brain , treatment Ipilimumab peptide vaccine initiate , without 21 day break . When radiotherapy use brain metastasis , treatment , however , initiated patient dependent prednisolone . 4 . Adequate haematological , renal hepatic function : Leukocytes ≥ 2 x 10^9 / l Neutrophils ≥ 1 x 10^9 / l Platelet count ≥ 75 x 10^9 / l Hemoglobin ≥ 5.6 mmol / l ( possibly transfusion ) Serum creatinine ≤ 2 time upper limit normal AST ALT ≤ 2.5 time upper normal limit ( ≤ 5 time upper normal limit consider increase due liver metastasis ) Serum bilirubin ≤ 2 time upper normal limit ( except patient Gilbert 's syndrome , allow bilirubin 3.0 mg / dL ) Exclusion criterion patient 1 . Concomitant immunosuppressive therapy include prednisolone methotrexate 2 . Known infection HIV , hepatitis B C virus , even infection remain stable medical treatment 3 . Other malignancy within past three year , squamous cell basal cell skin carcinoma 4 . Serious somatic disease , severe asthma , severe COPD , poorly control cardiovascular disease diabetes 5 . Patients must undergo major intestinal surgery within last 28 day . 6 . Severe allergy previous anaphylactoid reaction 7 . Pregnant lactate woman 8 . Psychiatric illness perceive investigator likely affect patient compliance 9 . Known hypersensitivity ingredient adjuvant substance Montanide Aldara cream Exclusion Criteria Vemurafenib peptide vaccine 1 . At least one follow within past six month : myocardial infarction , severe / unstable angina pectoris , symptomatic congestive heart failure , cerebrovascular event transient ischaemic attack , pulmonary embolism , poorly control hypertension , 2 . Congenital long QT syndrome , previous current significant ventricular atrial dysrhythmia ≥ 2nd degree ( NCI CTCAE version 4.0 ) 3 . Corrected QT interval ≥ 450 msec baseline 4 . Uncontrolled medical illness infection require intravenous antibiotic 5 . Other severe acute , chronic psychiatric condition abnormal laboratory value , increase risk associate Vemurafenib treatment Exclusion Criteria Ipilimumab peptide vaccine 1 . Autoimmune diseases : History inflammatory bowel disease , include Crohn 's disease ulcerative colitis , systemic autoimmune disease eg . rheumatoid arthritis , scleroderma , systemic lupus erythematosus , autoimmune vasculitis , include Wegener granulomatosis . Patients motor neuropathy believe autoimmune origin GuillainBarre Myasthenia gravis include study . 2 . Treatment vaccine prevent infection within 28 prior initiation treatment peptide vaccine Ipilimumab 3 . Systemic treatment prednisolone . 4 . Lifethreatening disease require treatment immunosuppressive agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>